Effects of lipoxin A4 on CoCl2-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells

Pharmacology

Volumn 84, Issue 1, 2009, Pages 17-23

  Liu, Songjun ^a   Wu, Ping ^b,d   Ye, Duyun ^b   Huang, Yinping ^a   Zhou, Xiaoyan ^c   Li, Yongsheng ^b   Cai, Lei ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NANCHANG UNIVERSITY   (China)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Human endothelial cell; Hypoxia; Hypoxia inducible factor 1 ; Lipoxin A4; Vascular endothelial growth factor

Indexed keywords

COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOXIN A; TRANSCRIPTION FACTOR ETV6; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL NUCLEUS; DOSE RESPONSE; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; CELL HYPOXIA; CELLS, CULTURED; COBALT; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOXINS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66149112902     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000221379     Document Type: Article

References (33)

1. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
2. Rössler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Süss R, Niemeyer CM, Vassal G: Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008; 44: 1645-1656.
3. Pourgholami MH, Morris DL: Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem 2008; 6: 343-347.
4. Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA: Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008; 8: 352.
5. Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, Kim YK, Chung SY, Choi SJ, Kim HJ, Chung IJ, Lee JJ: The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res 2009; 33: 665-670.
6. EI Tarhouny S, Seefeld M, Fan AX, Hahn S, Holzgreve W, Zhong XY: Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine 2008; 44: 65-69.
7. Schmidt M, Voelker HU, Kapp M, Dietl J, Kammerer U: Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage. Anticancer Res 2008; 28: 1719-1724. (Pubitemid 351892949)
8. Patel D, Bassi R, Hooper AT, Sun H, Huber J, Hicklin DJ, Kang X: Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal anti-bodies. Anticancer Res 2008; 28: 2679-2686.
9. Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, Wu Y, Zhu Z, Pytowski B, Liang Y, Zhong W, Vezzoni P, Rozell B, Cao Y: Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancerassociated systemic syndrome. Proc Natl Acad Sci USA 2008; 105: 18513-18518.
10. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
11. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008; 454: 436-444.
12. Aliberti J, Serhan C, Sher A: Parasite-induced lipoxin A 4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 2002; 196: 1253-1262.
13. Morris T, Stables M, Gilroy DW: New perspectives on aspirin and the endogenous control of acute inflammatory resolution. Sci World J 2006; 6: 1045-1068. (Pubitemid 44440819)
14. Zhou X-Y, Wu P, Zhang L, Xiong W, Li YS, Feng YM, Ye DY: Effects of lipoxin A 4 on lipopolysaccharide induced proliferation and reactive oxygen species production in RAW264.7 macrophages through modulation of G-CSF secretion. Inflamm Res 2007; 56: 324-333. (Pubitemid 47241093)
15. 2+ current ICRAC. Arch Biochem Biophys 2008; 7: 1-9.
16. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, Lee YH: Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci 2007; 22(suppl):S38-S46.
17. Wouters BG, Koritzinsky M: Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851-864.
18. Nardinocchi L, Puca R, Sacchi A, D'Orazi G: Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 2009; 8: 1.
19. Cao Y: Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 2008; 100: 113-131. (Pubitemid 351932181)
20. Kerbel RS, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
21. Reisfeld RA, Niethammer AG, Luo Y, Xiang R: DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int Arch Allergy Immunol 2004; 133: 295-304. (Pubitemid 38529223)
22. Kumar S, Li C: Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 2001; 22: 129-133. (Pubitemid 32675258)
23. Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 2008; 8: 579-591.
24. Rankin EB, Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
25. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
26. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T: Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2008; 295:G709-G717.
27. Jun HO, Kim Y, Kwon YW, Hong SS, Kim KW, Shin J, Kim TY: Wondonin, a novel compound, inhibits hypoxia-induced angio-genesis through hypoxia-inducible factor 1 alpha. FEBS Lett 2007; 581: 4977-4982. (Pubitemid 47542269)
28. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor-1α in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
29. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
30. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der Kogel AJ, Bussink J: Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 2009; 77: 96-103.
31. Tal R, Shaish A, Bangio L, Peled M, Breitbart E, Harats D: Activation of C-transactivation domain is essential for optimal HIF-1α -mediated transcriptional and angiogenic effects. Microvasc Res 2008; 76: 1-6.
32. Jośko J, Mazurek M: Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 2004; 10:RA89-RA98. (Pubitemid 38525095)
33. Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V, Villela CG, Barja-Fidalgo C, Fierro IM: ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008; 153: 956-965. (Pubitemid 351328942)